Susan C Glasser
Biographic Data
| ID | 6071495 |
|---|---|
| NAME | Susan C Glasser |
| GIVEN NAMES | Susan C |
| FAMILY NAME | Glasser |
| SIGNATURE | GLASSER S C |
| AFFILIATIONS | Jesse A. Berlin and Susan C. Glasser are with Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ. Susan S. Ellenberg is with the University of Pennsylvania School of Medicine Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA. |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 1 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2008 |
| LATEST PUBLICATION YEAR | 2008 |
| H-INDEX | 0 |
Adverse Event Detection in Drug Development
Premarketing studies of drugs, although large enough to demonstrate efficacy and detect common adverse events, cannot reliably detect an increased incidence of rare adverse events or events with significant latency. For most drugs, only about 500 to 3000 participants are studied, for relatively short durations, before a drug is marketed. Systems for assessment of postmarketing adverse events include spontaneous reports, computerized claims or med…
No prominent works on this page.
Adverse Event Detection in Drug Development
Premarketing studies of drugs, although large enough to demonstrate efficacy and detect common adverse events, cannot reliably detect an increased incidence of rare adverse events or events with significant latency. For most drugs, only about 500 to 3000 participants are studied, for relatively short durations, before a drug is marketed. Systems for assessment of postmarketing adverse events include spontaneous reports, computerized claims or med…
Adverse effect (1 works) · Biosimilars and Bioanalytical Methods (1 works) · Computational Drug Discovery Methods (1 works) · Drug (1 works) · Intensive care medicine (1 works) · Medicine (1 works) · Pharmaceutical Economics and Policy (1 works) · Pharmacology (1 works) · Pharmacology (1 works) · Pharmacovigilance (1 works)